Electrocardiographic changes in children and adolescents treated with ziprasidone: A prospective study

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 44, Issue 1, 2005, Pages 73-79

  Blair, Jennifer ^a   Scahill, Lawrence ^a   State, Matthew ^a   Martin, Andrés ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Electrocardiogram; QTc; Sudden death; Ziprasidone

Indexed keywords

ZIPRASIDONE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVELOPMENTAL DISORDER; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG SAFETY; ELECTROCARDIOGRAPHY; FEMALE; GILLES DE LA TOURETTE SYNDROME; HEART RATE VARIABILITY; HUMAN; MALE; OBSESSIVE COMPULSIVE DISORDER; OUTPATIENT CARE; PARAMETER; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOPHARMACOLOGY; PULSE RATE; QRS COMPLEX; QT INTERVAL; SCHOOL CHILD; STATISTICAL SIGNIFICANCE;

EID: 10944231099     PISSN: 08908567     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.chi.0000145372.61239.bb     Document Type: Article

References (48)

1. Algra A, Tijssen JG, Roelandt JR, Pool J, Lubsen J (1993), QT interval variables from 24 hour electrocardiography and the two year risk of sudden death. Br Heart J 70:43-48
2. Al-Khatib SM, LaPointe NM, Kramer JM, Califf RM (2003), What clinicians should know about the QT interval. JAMA 289:2120-2127
3. Allison DB, Mentore JL, Heo M et al. (1999), Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156:1686-1696
4. Aman MG, Richmond G, Stewart AW, Bell JC, Kissel RC (1987), The aberrant behavior checklist: factor structure and the effect of subject variables in American and New Zealand facilities. Am J Ment Defic 91:570-578
5. Anderson ME, Al-Khatib SM, Roden DM, Califf RM (2002), Cardiac repolarization: current knowledge, critical gaps, and new approaches to drug development and patient management. Am Heart J 144:769-781
6. Anonymous (2000), Application Number 20-825 Medical Review. Available at http://www.fda.gov/cder/foi/nda/2001/20-825_Geodon_medr_P4.pdf. Accessed March 16, 2004
7. Anonymous (2001), Important Drug Warning, Inapsine (droperidol). Available at http://www.fda.gov/medwatch/safety/2001/inapsine.htm. Accessed September 4, 2003
8. Anonymous (2002), Package insert, Geodon (ziprasidone). Available at: http://www.pfizer.com/download/uspi_geodon.pdf. Accessed September 4, 2003
9. Arato M, O'Connor R, Meltzer HY (2002), A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int Clin Psychopharmacol 17:207-215
10. Bazett H (1918), An analysis of the time-relations of electrocardiograms. Heart 7:353-370
11. Bednar MM, Harrigan EP, Anziano RJ, Camm AJ, Ruskin JN (2001), The QT interval. Prog Cardiovasc Dis 43:1-45
12. Blair J, Taggart B, Martin A (2004), Electrocardiographic safety profile and monitoring guidelines in pediatric psychopharmacology. J Neural Transm 111:791-815
13. Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M (1999), Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology 20:491-505
14. Desta Z, Kerbusch T, Flockhart DA (1999), Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6). Clin Pharmacol Ther 65:10-20
15. Flockhart DA, Drici MD, Kerbusch T et al. (2000), Studies on the mechanism of a fatal clarithromycin-pimozide interaction in a patient with Tourette syndrome. J Clin Psychopharmacol 20:317-324
16. Fulop G, Phillips RA, Shapiro AK, Gomes JA, Shapiro E, Nordlie JW (1987), ECG changes during haloperidol and pimozide treatment of Tourette's disorder. Am J Psychiatry 144:673-675
17. Garson A Jr (1993), How to measure the QT interval-what is normal? Am J Cardiol 72:14B-16B
18. Gordon M (2000), Ziprasidone, NDA #20825: Study report of Clinical Pharmacology Protocol #128-054. Available at http://www.fda. gov/ohrms/dockets/ac/00/backgrd/3619b1b.pdf. Accessed March 3, 2004
19. Gutgesell H, Atkins D, Barst R et al. (1999), AHA scientific statement: cardiovascular monitoring of children and adolescents receiving psychotropic drugs. J Am Acad Child Adolesc Psychiatry 38:1047-1050
20. Guy W (1976), Clinical Global Impression (CGI). In: ECDEU Assessment Manual for Psychopharmacology (publication no. 76-338). Washington, DC: US Department of Health, Education and Welfare
21. Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr (1992), Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 52:231-238
22. Jekel JF, Elmore JG, Katz DL (1996), Epidemiology, Biostatistics, and Preventive Medicine. Philadelphia: Saunders
23. Jurima-Romet M, Crawford K, Cyr T, Inaba T (1994), Terfenadine metabolism in human liver. In vitro inhibition by macrolide antibiotics and azole antifungals. Drug Metab Dispos 22:849-857
24. Kautzner J (2002), QT interval measurements. Card Electrophysiol Rev 6:273-277
25. Keck PE Jr, Reeves KR, Harrigan EP (2001), Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double-blind, placebo-controlled, multicenter studies. J Clin Psychopharmacol 21:27-35
26. Keck PE Jr, Versiani M, Potkin S, West SA, Giller E, Ice K (2003), Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry 160:741-748
27. Labellarte MJ, Crosson JE, Riddle MA (2003), The relevance of prolonged QTc measurement to pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry 42:642-650
28. Leckman JF, Riddle MA, Hardin MT et al. (1989), The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity. J Am Acad Child Adolesc Psychiatry 28:566-573
29. Malik M, Camm AJ (2001), Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling. Drug Saf 24:323-351
30. Malone RP, Delaney MA, Gifford C (2003), Ziprasidone treatment-associated changes in QTc and weight in adolescents with autism. Poster presented at the Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Miami, October
31. McDougle CJ, Kem DL, Posey DJ (2002), Case series: use of ziprasidone for maladaptive symptoms in youths with autism. J Am Acad Child Adolesc Psychiatry 41:921-927
32. Miller MD, Porter C, Ackerman MJ (2001), Diagnostic accuracy of screening electrocardiograms in long QT syndrome I. Pediatrics 108:8-12
33. Morganroth J, Brozovich FV, McDonald JT, Jacobs RA (1991), Variability of the QT measurement in healthy men, with implications for selection of an abnormal QT value to predict drug toxicity and proarrhythmia. Am J Cardiol 67:774-776
34. Moss AJ (1993), Measurement of the QT interval and the risk associated with QTc interval prolongation: a review. Am J Cardiol 72:23B-25B
35. Moss AJ, Schwartz PJ (1982), Delayed repolarization (QT or QTU prolongation) and malignant ventricular arrhythmias. Mod Concepts Cardiovasc Dis 51:85-90
36. Patel NC, Sierk P, Dorson PG, Crismon L (2002), Experience with ziprasidone. J Am Acad Child Adolesc Psychiatry 41:495
37. Pezawas L, Quiner S, Moertl D et al. (2000), Efficacy, cardiac safety and tolerability of sertindole: a drug surveillance. Int Clin Psychopharmacol 15:207-214
38. Priori SG, Schwartz PJ, Napolitano C et al. (2003), Risk stratification in the long-QT syndrome. N Engl J Med 348:1866-1874
39. Rautaharju PM, Zhou SH, Wong S et al. (1992), Sex differences in the evolution of the electrocardiographic QT interval with age. Can J Cardiol 8:690-695
40. Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SH (2000), QTc-interval abnormalities and psychotropic drug therapy in patients. Lancet 355:1048-1052
41. Sallee FR, Kurlan R, Goetz CG et al. (2000), Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study. J Am Acad Child Adolesc Psychiatry 39:292-299
42. Scahill L, Leckman JF, Schultz RT, Katsovich L, Peterson BS (2003), A placebo-controlled trial of risperidone in Tourette syndrome. Neurology 60:1130-1135
43. Scahill L, McCracken J, McDougle CJ et al. (2001), Methodological issues in designing a multisite trial of risperidone in children and adolescents with autism. J Child Adolesc Psychopharmacol 11:377-388
44. Scahill L, Riddle MA, McSwiggin-Hardin M et al. (1997), Children's Yale-Brown Obsessive Compulsive Scale: reliability and validity. J Am Acad Child Adolesc Psychiatry 36:844-852
45. Schmidt AW, Lebel LA, Howard HR Jr, Zorn SH (2001), Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol 425:197-201
46. Shapiro E, Shapiro AK, Fulop G et al. (1989), Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette's syndrome. Arch Gen Psychiatry 46:722-730
47. Vervaet P, Amery W (1993), Reproducibility of QTc-measurements in healthy volunteers. Acta Cardiol 48:555-564
48. Wilens TE, Biederman J, Baldessarini RJ et al. (1996), Cardiovascular effects of therapeutic doses of tricyclic antidepressants in children and adolescents. J Am Acad Child Adolesc Psychiatry 35:1491-1501